(CercleFinance.com) – Crossject announces that it has hired Syneos Health, a biopharmaceutical laboratory services group, to prepare for the commercial launch in the United States of Zepizure, its innovative emergency treatment for the management of epileptic seizures.
As part of this agreement, Syneos Health will provide support for all pre-launch and product launch activities, providing Crossject with the benefit of its presence in the United States and its expertise in bringing new treatments to market.
In 2022, Crossject was awarded a contract with BARDA, for the advanced regulatory development and supply of Zepizure to the United States Strategic National Stockpile (SNS), upon FDA authorization.